The funds will be used to conduct studies on Iantrek’s Micro-Interventional Glaucoma Surgical devices in the U.S.
Iantrek is the only glaucoma surgical company with FDA-registered technology to target outflow pathways.
“There remains a significant unmet clinical need to provide safe and effective micro-interventional tools for aqueous outflow management,” Sean Ianchulev, MD, Iantrek’s founder and CEO, said in an Aug. 30 press release. “We are grateful to have a world-class syndicate of investors supporting our efforts to advance these new technologies. With two commercial ready [Micro-Interventional Glaucoma Surgical] platforms, Iantrek is uniquely positioned to transform the horizon of micro-interventional ophthalmic surgery.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
